Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.60 |
| ▸ | MMP12 | P39900 | 7/20 | 0.60 |
| ▸ | MMP13 | P45452 | 7/20 | 0.60 |
| ▸ | MMP14 | P50281 | 7/20 | 0.60 |
| ▸ | MMP9 | P14780 | 6/20 | 0.60 |
| ▸ | MMP1 | P03956 | 5/20 | 0.60 |
| ▸ | MMP3 | P08254 | 5/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 6/20 | 0.46 |
| ▸ | MMP16 | P51512 | 6/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511247 | 0.85 | HTR6 (0.52) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL3394732 | 0.83 | CYP2D6 (0.83) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL31356940 | 0.83 | CYP2D6 (0.46) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL1148229 | 0.81 | GAA (0.44) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL29196139 | 0.77 | CA1 (0.50) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL10355100 | 0.76 | HSD11B1 (0.57) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL2474755 | 0.76 | HTR2A (0.59) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL3157495 | 0.75 | CYP2D6 (1.00) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL3157502 | 0.75 | CYP2D6 (1.00) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL3152842 | 0.74 | CYP2D6 (0.73) | MMP2MMP12MMP13MMP14MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060026-A1 | Indoles Active on CRTH2 Receptor | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2245010-A1 | INDOLES ACTIVE ON CRTH2 RECEPTOR | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009090399-A1 | INDOLES ACTIVE ON CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060026-A1 | Indoles Active on CRTH2 Receptor | ARRB1, GPR3, HRH3 | MMP2 4461/4885MMP12 4334/4885MMP13 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.